Teva and Spectrum settle patent dispute over Folotyn

Teva and Spectrum Pharmaceuticals have settled a patent dispute over the generic version of Folotyn (pralatrexate injection), a treatment for patients with relapsed or refractory peripheral T-cell lymphoma.

The settlement will allow Teva to begin marketing the generic drug in the US on December 1, 2022, or earlier under certain conditions.

The companies will submit the agreement to the Federal Trade Commission and the Department of Justice.

Spectrum said that it will request the dismissal of the litigation against Teva, while litigation against other generic filers will continue.

Teva develops, manufactures, markets and distributes generic medicines worldwide. It is the largest generic drug manufacturer in the world.